NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven...

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• NOTCH1 mutations in chronic lymphocytic leukemia (CLL) are linked to rituximab resistance.
• The underlying mechanisms for this resistance, particularly concerning CD20 expression, require elucidation.

Purpose of the Study:

• To investigate the association between NOTCH1 mutations and CD20 expression in CLL.
• To elucidate the molecular mechanisms, including epigenetic regulation, by which NOTCH1 mutations affect CD20 levels.

Main Methods:

• Analysis of CD20 expression in a large cohort of CLL patients (n=692) stratified by NOTCH1 mutation status.
• In vitro studies using γ-secretase inhibitors, small interfering RNA, and gene transfection to manipulate NOTCH1 signaling.
• Investigation of protein-protein interactions involving RBPJ, NICD, and HDACs at the CD20 gene promoter.
• Treatment with histone deacetylase (HDAC) inhibitors.

Main Results:

• NOTCH1-mutated CLL cells exhibit significantly lower CD20 expression and reduced sensitivity to anti-CD20-mediated lysis.
• NOTCH1 intracellular domain (NICD) directly downregulates CD20 at both protein and transcript levels.
• NOTCH1 mutations promote RBPJ complex formation with NICD, leading to increased HDAC recruitment and epigenetic repression of the CD20 gene.
• HDAC inhibition, including with valproic acid, upregulates CD20 expression in both cell lines and primary CLL cells.

Conclusions:

• NOTCH1 mutations are a key factor in reducing CD20 expression in CLL.
• Epigenetic dysregulation involving HDACs is the primary mechanism by which NOTCH1 mutations suppress CD20.
• Targeting epigenetic pathways may offer strategies to overcome rituximab resistance in NOTCH1-mutated CLL.